Sizhen Wang

Sizhen Wang

Auto-generated profile, based on publicly available information

Sizhen Wang

Research Institute of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
SWSizhen Wang
Sizhen Wang
GYGuangjie Yu
Guangjie Yu
YDYanzhenzi Dai
Yanzhenzi Dai
CGChi Gan
Chi Gan
SQShuyi Qiu
Shuyi Qiu
HHHong-Ming Hu
Hong-Ming Hu
Purpose: To develop adoptive T-cell therapy with genetically engineered T-cell receptor (TCR; TCR-T) that recognizes the KRASG12V mutation, we performed an Investigational New Drug (IND)-enabling preclinical study of a new TCR (051). This TCR was isolated from a patient with pancreatic ductal adenocarcinoma with the KRASG12V mutation that could be presented by the HLA-A*11:01 allele, the most common allele of the Chinese population. Experimental Design: In vitro experiments using T cells from healthy donors transduced with a retroviral vector expressing 051 TCR were performed to determine the TCR specificity and functionality. The tumor reactivity strictly depended on the expression of the G12V mutation and HLA-A*11:01 molecules. The alanine scan experiment did not detect potential “off-target” cross-reactivity against the human genome. Good Laboratory Practice studies were carried out to assess the antitumor efficacy, persistence, safety, and toxicities of adoptively transferred human 051 TCR-T cells (IX001) in immunodeficient mice bearing human pancreatic cancer xenografts. Results: After T-cell infusion, a potent antitumor effect was observed with or without IL-2 administration. The analysis of TCR gene integration in host T cells by retrovirus indicated a low risk of developing secondary malignancy. There was no evidence of TCR-T–related toxicity and genotoxicity induced by the retroviral vector. Conclusions: IX001 was safe and highly efficacious in a pancreatic cancer CDX model. Our data support further clinical development of IX001 for HLA-A*11:01 patients with the KRASG12V mutation.

3 November 2025
Verified
Other
Open access
SWSizhen Wang
Sizhen Wang
GYGuangjie Yu
Guangjie Yu
YDYanzhenzi Dai
Yanzhenzi Dai
CGChi Gan
Chi Gan
SQShuyi Qiu
Shuyi Qiu
HHHong-Ming Hu
Hong-Ming Hu
In vitro analysis of 051 TCR-T.


3 November 2025
Verified
Other
Open access
SWSizhen Wang
Sizhen Wang
GYGuangjie Yu
Guangjie Yu
YDYanzhenzi Dai
Yanzhenzi Dai
CGChi Gan
Chi Gan
SQShuyi Qiu
Shuyi Qiu
HHHong-Ming Hu
Hong-Ming Hu
The antibody used for staining.

3 November 2025
Verified
Other
Open access
SWSizhen Wang
Sizhen Wang
GYGuangjie Yu
Guangjie Yu
YDYanzhenzi Dai
Yanzhenzi Dai
CGChi Gan
Chi Gan
SQShuyi Qiu
Shuyi Qiu
HHHong-Ming Hu
Hong-Ming Hu
TCR-T cells toxicity analysis in vivo.

3 November 2025
Verified
Other
Open access
SWSizhen Wang
Sizhen Wang
GYGuangjie Yu
Guangjie Yu
YDYanzhenzi Dai
Yanzhenzi Dai
CGChi Gan
Chi Gan
SQShuyi Qiu
Shuyi Qiu
HHHong-Ming Hu
Hong-Ming Hu
Certificate of analysis of the preclinical grade 051 TCR-T.